

2024

Public engagement highlights

Annual overview of patients and healthcare professionals involvement in EMA's work

In 2024, representatives of patients, consumers and healthcare professionals (HCP) actively contributed to better EMA's work in many ways. They participated in multistakeholder workshops and other initiatives, and continued to provide valuable input on EMA documents to ensure that these documents are clear to the patients and healthcare professionals who read them. They also engaged in [early dialogue with CHMP](#), contributed to the [EMANS strategy to 2028](#) and joined the [ACT EU Multistakeholder platform](#) advisory group as members. Finally, this year also saw the launch of the revamped Human Medicines Highlights [newsletter](#) and an [Open Call](#) aimed at remunerating patients, consumers and HCP experts for their work with EMA.



Stakeholder involvement in medicine-related activities

Patient contribution to EMA's work

Patient membership numbers	39
EMA Management Board	2
Scientific committees	15
Patients' and Consumers' Working Party	22
Active patient experts	186
Patients/consumers eligible organisations	41

HCP contribution to EMA's work

HCP membership numbers	36
EMA Management Board	2
Scientific committees	12
HCP Working Party	22
Active HCP experts	155
HCP eligible organisations	41

Working party meetings

February

Third-party interventions, activities in cancer area, PED, pharmacovigilance, shortages, policy on competing interests, EMA Working Party operations

[Access meeting documents](#)

July

EMANS to 2028, Clinical trial (CT) activities, product information, transparency activities, shortages, vaccine related updates, biosimilar medicines


[Access meeting documents](#)

November

CTs updates, sustainability of the network, shortages, medical devices, EMA data-related initiatives and digitalisation, artificial intelligence, communication activities

[Access meeting documents](#)

Queries by stakeholder



■ Patients ■ HCPs ■ Others

Total number queries: **1450**

Overall satisfaction: **77%**

Common topics:

COVID-19 vaccines, availability, ADRs, GLP-1 receptor agonists

Key events

Multistakeholder workshop on psychedelics

In April 2024, a multi-stakeholder workshop brought together patients, HCPs, academia, regulators, and industry to discuss the development and therapeutic use of psychedelic substances to address unmet medical needs in the area of mental health.

[View event summary](#) | [Workshop documents](#)

Multistakeholder workshop on shortages of Glucagon-Like Peptide-1 (GLP-1) receptor agonists

In July 2024, the multistakeholder workshop aimed to clarify the needs and challenges of different stakeholder groups in relation to shortages of GLP-1 receptor agonists, share experiences of ongoing activities to mitigate and prevent these shortages, identify novel solutions, strengthen cooperation among stakeholders, and agree on key messages for communication to effectively reach target audiences.

[View event summary](#) | [Workshop documents](#)

Patient and HCP engagement in medicine-specific activities

Patients in scientific advice procedures	70
Patients in scientific advisory groups	27
Patients in committee consultations	25
Responses to CHMP early dialogue	21
Review of documents by patients	98

HCP experts in scientific advisory groups	186
Responses to CHMP early dialogue	35
Review of documents by HCP	52